DK1793844T3 - Anvendelse af [D-MeAla]3-[EtVal]4-cyklosporin til behandling af hepatitis C-infektion - Google Patents

Anvendelse af [D-MeAla]3-[EtVal]4-cyklosporin til behandling af hepatitis C-infektion

Info

Publication number: DK1793844T3
Authority: DK; Denmark
Prior art keywords: cyclosporin; treatment; infection; etval; meala
Prior art date: 2004-10-01

Application number

DK05791430.1T

Other languages

English (en)

Inventor

Pietro Scalfaro

Jean-Maurice Dumont

Gregoire Vuagniaux

Rolland-Yves Mauvernay

Original Assignee

Debiopharm Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-10-01

Filing date

2005-10-03

Publication date

2011-03-21

2005-10-03 Application filed by Debiopharm Sa filed Critical Debiopharm Sa

2011-03-21 Application granted granted Critical

2011-03-21 Publication of DK1793844T3 publication Critical patent/DK1793844T3/da

Links

229960001265 ciclosporin Drugs 0.000 title abstract 2
208000005176 Hepatitis C Diseases 0.000 title 1
208000010710 hepatitis C virus infection Diseases 0.000 title 1
239000013543 active substance Substances 0.000 abstract 2
102000001493 Cyclophilins Human genes 0.000 abstract 1
108010068682 Cyclophilins Proteins 0.000 abstract 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
229930105110 Cyclosporin A Natural products 0.000 abstract 1
108010036949 Cyclosporine Proteins 0.000 abstract 1
230000027455 binding Effects 0.000 abstract 1
229930182912 cyclosporin Natural products 0.000 abstract 1
230000001506 immunosuppresive effect Effects 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Virology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

DK05791430.1T 2004-10-01 2005-10-03 Anvendelse af [D-MeAla]3-[EtVal]4-cyklosporin til behandling af hepatitis C-infektion DK1793844T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IB2004003205		2004-10-01
PCT/IB2005/002940 WO2006038088A1 (en)	2004-10-01	2005-10-03	Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3-[etval]4-cyclosporin

Publications (1)

Publication Number	Publication Date
DK1793844T3 true DK1793844T3 (da)	2011-03-21

Family

ID=34959441

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK05791430.1T DK1793844T3 (da)	2004-10-01	2005-10-03	Anvendelse af [D-MeAla]3-[EtVal]4-cyklosporin til behandling af hepatitis C-infektion

Country Status (29)

Country	Link
US (3)	US7439227B2 (da)
EP (1)	EP1793844B1 (da)
JP (1)	JP4892486B2 (da)
KR (1)	KR101191833B1 (da)
CN (1)	CN101056648B (da)
AT (1)	ATE490778T1 (da)
AU (1)	AU2005290984B2 (da)
BR (1)	BRPI0515494A (da)
CA (1)	CA2580448C (da)
CY (1)	CY1114594T1 (da)
DE (1)	DE602005025232D1 (da)
DK (1)	DK1793844T3 (da)
EA (1)	EA012650B1 (da)
ES (1)	ES2357587T3 (da)
GE (1)	GEP20104960B (da)
HR (1)	HRP20110169T1 (da)
IL (1)	IL182362A0 (da)
MA (1)	MA28950B1 (da)
MX (1)	MX2007003387A (da)
NZ (1)	NZ554412A (da)
PL (1)	PL1793844T3 (da)
PT (1)	PT1793844E (da)
RS (1)	RS51614B (da)
SG (1)	SG139750A1 (da)
SI (1)	SI1793844T1 (da)
TN (1)	TNSN07084A1 (da)
UA (1)	UA88484C2 (da)
WO (1)	WO2006038088A1 (da)
ZA (1)	ZA200702610B (da)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0320638D0 (en)	2003-09-03	2003-10-01	Novartis Ag	Organic compounds
KR20070036175A (ko)	2004-07-14	2007-04-02	노파르티스 아게	Ｃ형 간염(ｈｃｖ)의 치료를 위한 시클로스포린과ｐｅｇ화된 인터페론의 조합 제제의 용도
US7196161B2 (en)	2004-10-01	2007-03-27	Scynexis Inc.	3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
ATE412005T1 (de)	2004-11-22	2008-11-15	Astellas Pharma Inc	Zyklosporinanalog
WO2006071619A1 (en) *	2004-12-23	2006-07-06	Novartis Ag	Compositions for hcv treatment
AU2005322241B2 (en) *	2004-12-23	2010-02-18	Novartis Ag	Compounds for flaviviridae treatment
CA2611151A1 (en) *	2005-06-17	2006-12-28	Novartis Ag	Use of sanglifehrin in hcv
ATE498630T1 (de)	2005-09-30	2011-03-15	Scynexis Inc	Arylalkyl- und heteroarylalkyl-derivate von cyclosporin a bei der behandlung und vorbeugung einer virusinfektion
CN105169369B (zh)	2005-09-30	2019-10-18	中美华世通生物医药科技（武汉）有限公司	治疗和预防丙型肝炎感染的方法和药物组合物
KR101273681B1 (ko)	2005-10-26	2013-06-25	아스텔라스세이야쿠 가부시키가이샤	신규 시클릭 펩티드 화합물
BRPI0710878A2 (pt)	2006-04-11	2015-03-31	Novartis Ag	Compostos orgânicos e seus usos
JP5377293B2 (ja)	2006-05-19	2013-12-25	スシネキスインク	眼疾患の治療及び予防方法
AU2007306316B2 (en) *	2006-10-12	2011-10-27	Kyushu University	Use of modified cyclosporins
US7576057B2 (en)	2006-11-20	2009-08-18	Scynexis, Inc.	Cyclic peptides
CN101687012A (zh)	2007-05-02	2010-03-31	安斯泰来制药有限公司	新的环肽化合物
WO2009042892A1 (en)	2007-09-26	2009-04-02	Oregon Health & Science University	Cyclic undecapeptides and derivatives as multiple sclerosis therapies
WO2009098533A1 (en) *	2008-02-08	2009-08-13	Debiopharm Sa	Non -immunosuppressive cyclosporin for the treatment of muscular dystrophy
WO2009148615A1 (en) *	2008-06-06	2009-12-10	Scynexis, Inc.	Cyclosporin analogs and their use in the treatment of hcv infections
CA2724523A1 (en)	2008-06-06	2010-01-07	Scynexis, Inc.	Novel macrocyclic peptides
JP5758806B2 (ja) *	2008-11-06	2015-08-05	デビオルシェルシュファルマスーティクソシエテアノニムＤｅｂｉｏＲｅｃｈｅｒｃｈｅＰｈａｒｍａｃｅｕｔｉｑｕｅＳｏｃｉｅｔｅＡｎｏｎｙｍｅ	シクロウンデカデプシペプチド化合物および医薬としてのその化合物の使用
CN102307892A (zh)	2008-12-31	2012-01-04	西尼克斯公司	环孢菌素a的衍生物
JP5406943B2 (ja)	2009-01-30	2014-02-05	エナンタファーマシューティカルズインコーポレイテッド	Ｃ型肝炎感染を予防または治療するためのシクロスポリンアナログ
US8481483B2 (en)	2009-02-19	2013-07-09	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
US20110182850A1 (en)	2009-04-10	2011-07-28	Trixi Brandl	Organic compounds and their uses
US8512690B2 (en)	2009-04-10	2013-08-20	Novartis Ag	Derivatised proline containing peptide compounds as protease inhibitors
US8349312B2 (en)	2009-07-09	2013-01-08	Enanta Pharmaceuticals, Inc.	Proline substituted cyclosporin analogues
US8685917B2 (en)	2009-07-09	2014-04-01	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
US8367053B2 (en)	2009-07-09	2013-02-05	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
WO2011063076A1 (en)	2009-11-19	2011-05-26	Itherx Pharmaceuticals, Inc.	Methods of treating hepatitis c virus with oxoacetamide compounds
JP2013513595A (ja)	2009-12-09	2013-04-22	サイネクシス，インコーポレーテッド	新規環状ペプチド
US8623814B2 (en)	2010-02-23	2014-01-07	Enanta Pharmaceuticals, Inc.	Antiviral agents
WO2011141891A1 (en)	2010-05-12	2011-11-17	Debio Recherche Pharmaceutique S.A.	Use of cycloundecadepsipeptide compounds
US9217015B2 (en)	2010-07-16	2015-12-22	S&T Global Inc.	Cyclosporin derivatives for the treatment and prevention of a viral infection
US9573978B2 (en)	2010-08-12	2017-02-21	S&T Global, Inc.	Cyclosporin derivatives for the treatment and prevention of a viral infection
AU2011311706B2 (en)	2010-10-05	2015-11-12	Debiopharm S.A.	New treatments of Hepatitis C virus infection
EA201390532A1 (ru)	2010-10-08	2013-09-30	Новартис Аг	Композиции сульфамидых ингибиторов ns3, содержащие витамин е
JP6110791B2 (ja) *	2010-11-30	2017-04-05	ノバルティスアーゲー	Ｃ型肝炎ウイルス感染症の新規治療
US9890198B2 (en)	2010-12-03	2018-02-13	S&T Global Inc.	Cyclosporin derivatives and uses thereof
JO3337B1 (ar) *	2010-12-13	2019-03-13	Debiopharm Sa	تركيبات صيدلية تشمل أليسبوريفير
MX2013011256A (es)	2011-03-31	2013-10-17	Novartis Ag	Alisporivir para el tratamiento de la infeccion por el virus de hepatitis c.
RU2013148779A (ru)	2011-04-01	2015-05-10	Новартис Аг	Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени
US20150104415A1 (en) *	2011-04-13	2015-04-16	Debiopharm International Sa	Treatments of Hepatitis C virus infection
AU2012314517A1 (en) *	2011-09-27	2014-04-17	Novartis Ag	Alisporivr for treatment of Hepatis C virus infection
US8466159B2 (en)	2011-10-21	2013-06-18	Abbvie Inc.	Methods for treating HCV
DE112012003510T5 (de)	2011-10-21	2015-03-19	Abbvie Inc.	Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8492386B2 (en)	2011-10-21	2013-07-23	Abbvie Inc.	Methods for treating HCV
CN104023726A (zh)	2011-10-21	2014-09-03	艾伯维公司	用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
CN104284671A (zh)	2012-05-07	2015-01-14	诺华股份有限公司	使用阿拉泊韦的药代动力学调节
AR090964A1 (es) *	2012-05-09	2014-12-17	Novartis Ag	Proceso para la elaboracion de undecapeptidos ciclicos
US8906853B2 (en)	2012-11-28	2014-12-09	Enanta Pharmaceuticals, Inc.	[N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
US20140205566A1 (en)	2012-11-30	2014-07-24	Novartis Ag	Cyclic nucleuoside derivatives and uses thereof
WO2015008223A1 (en)	2013-07-17	2015-01-22	Novartis Ag	Treatment of hepatitis c virus infection with alisporivir and ribavirin
EP3038626A4 (en)	2013-08-26	2017-04-19	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues for preventing or treating hepatitis c
WO2015136455A1 (en)	2014-03-13	2015-09-17	Novartis Ag	New treatments of hepatitis c virus infection
WO2016073480A1 (en)	2014-11-03	2016-05-12	Enanta Pharmaceuticals, Inc.	Novel cyclosporin analogues for preventing or treating hepatitis c infection
EA201892448A1 (ru)	2016-04-28	2019-06-28	Эмори Юниверсити	Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
WO2018207904A1 (ja)	2017-05-12	2018-11-15	中外製薬株式会社	環状有機化合物の製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2757522B1 (fr) *	1996-12-24	1999-01-29	Rhone Poulenc Rorer Sa	Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) *	1996-12-24	1999-01-29	Rhone Poulenc Rorer Sa	Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
GB9811854D0 (en) *	1998-06-02	1998-07-29	Ciba Geigy Ag	Organic compounds
MXPA00013019A (es) *	1998-07-01	2003-07-14	Debiopharm Sa	Ciclosporina novedosa con perfil de actividad mejorado.
GB0320638D0 (en) *	2003-09-03	2003-10-01	Novartis Ag	Organic compounds

2005
- 2005-10-03 EA EA200700725A patent/EA012650B1/ru not_active IP Right Cessation
- 2005-10-03 DE DE602005025232T patent/DE602005025232D1/de not_active Expired - Lifetime
- 2005-10-03 CA CA2580448A patent/CA2580448C/en not_active Expired - Fee Related
- 2005-10-03 SG SG200800480-6A patent/SG139750A1/en unknown
- 2005-10-03 GE GEAP200510037A patent/GEP20104960B/en unknown
- 2005-10-03 CN CN2005800332843A patent/CN101056648B/zh not_active Expired - Fee Related
- 2005-10-03 WO PCT/IB2005/002940 patent/WO2006038088A1/en not_active Ceased
- 2005-10-03 PL PL05791430T patent/PL1793844T3/pl unknown
- 2005-10-03 BR BRPI0515494-4A patent/BRPI0515494A/pt not_active IP Right Cessation
- 2005-10-03 JP JP2007534110A patent/JP4892486B2/ja not_active Expired - Fee Related
- 2005-10-03 AT AT05791430T patent/ATE490778T1/de active
- 2005-10-03 EP EP05791430A patent/EP1793844B1/en not_active Expired - Lifetime
- 2005-10-03 HR HR20110169T patent/HRP20110169T1/hr unknown
- 2005-10-03 DK DK05791430.1T patent/DK1793844T3/da active
- 2005-10-03 ES ES05791430T patent/ES2357587T3/es not_active Expired - Lifetime
- 2005-10-03 KR KR1020077007285A patent/KR101191833B1/ko not_active Expired - Fee Related
- 2005-10-03 SI SI200531225T patent/SI1793844T1/sl unknown
- 2005-10-03 AU AU2005290984A patent/AU2005290984B2/en not_active Ceased
- 2005-10-03 NZ NZ554412A patent/NZ554412A/en not_active IP Right Cessation
- 2005-10-03 RS RS20110108A patent/RS51614B/sr unknown
- 2005-10-03 PT PT05791430T patent/PT1793844E/pt unknown
- 2005-10-03 UA UAA200704937A patent/UA88484C2/ru unknown
- 2005-10-03 MX MX2007003387A patent/MX2007003387A/es active IP Right Grant
2006
- 2006-04-12 US US11/406,800 patent/US7439227B2/en not_active Ceased
2007
- 2007-03-08 TN TNP2007000084A patent/TNSN07084A1/en unknown
- 2007-03-28 ZA ZA200702610A patent/ZA200702610B/xx unknown
- 2007-04-01 IL IL182362A patent/IL182362A0/en not_active IP Right Cessation
- 2007-04-27 MA MA29858A patent/MA28950B1/fr unknown
2008
- 2008-08-26 US US12/230,198 patent/US7772184B2/en not_active Expired - Fee Related
2010
- 2010-10-29 US US12/915,370 patent/USRE43371E1/en not_active Expired - Fee Related
2011
- 2011-03-08 CY CY20111100263T patent/CY1114594T1/el unknown

Also Published As

Publication number	Publication date
WO2006038088A1 (en)	2006-04-13
PT1793844E (pt)	2011-03-10
HRP20110169T1 (hr)	2011-04-30
KR101191833B1 (ko)	2012-10-16
US20090081164A1 (en)	2009-03-26
EA200700725A1 (ru)	2007-10-26
HK1104236A1 (en)	2008-01-11
ES2357587T3 (es)	2011-04-27
PL1793844T3 (pl)	2011-05-31
UA88484C2 (ru)	2009-10-26
DE602005025232D1 (de)	2011-01-20
SG139750A1 (en)	2008-02-29
JP4892486B2 (ja)	2012-03-07
AU2005290984A1 (en)	2006-04-13
RS51614B (sr)	2011-08-31
EA012650B1 (ru)	2009-12-30
US7439227B2 (en)	2008-10-21
IL182362A0 (en)	2007-07-24
CA2580448C (en)	2012-09-18
JP2008514690A (ja)	2008-05-08
CN101056648B (zh)	2012-08-15
SI1793844T1 (sl)	2011-05-31
USRE43371E1 (en)	2012-05-08
EP1793844B1 (en)	2010-12-08
ZA200702610B (en)	2008-08-27
EP1793844A1 (en)	2007-06-13
NZ554412A (en)	2011-01-28
CA2580448A1 (en)	2006-04-13
MX2007003387A (es)	2007-05-23
MA28950B1 (fr)	2007-10-01
GEP20104960B (en)	2010-04-26
CN101056648A (zh)	2007-10-17
CY1114594T1 (el)	2016-10-05
BRPI0515494A (pt)	2008-07-29
TNSN07084A1 (en)	2008-06-02
US20060252675A1 (en)	2006-11-09
KR20070073761A (ko)	2007-07-10
AU2005290984B2 (en)	2010-09-09
US7772184B2 (en)	2010-08-10
ATE490778T1 (de)	2010-12-15

Publication	Publication Date	Title
DK1793844T3 (da)	2011-03-21	Anvendelse af [D-MeAla]3-[EtVal]4-cyklosporin til behandling af hepatitis C-infektion
WO2006033995A3 (en)	2006-06-01	Thiazolidin-4-ones having anti-hepatitis b activity
WO2009055335A3 (en)	2009-07-16	Hcv protease inhibitors
HUE036559T2 (hu)	2018-07-30	Készítmények telomeráz aktivitás fokozására és HIV fertõzés kezelésére
WO2005095403A3 (en)	2005-12-01	Macrocyclic compounds as inhibitors of viral replication
WO2007092645A3 (en)	2007-10-04	Novel hcv inhibitor combinations and methods
UA88463C2 (ru)	2009-10-26	Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
WO2005121138A3 (en)	2009-03-05	Heterotricyclic compounds for use as hcv inhibitors
WO2001012228A3 (en)	2001-08-30	Compositions for treating viral infections, and methods therefor
WO2006034001A3 (en)	2006-11-23	Methods of treating hiv infection
EP2071030A3 (en)	2009-07-22	Oligoribonucleotide or peptide nucleic acid which inhibits action of hepatitis C virus
ATE414092T1 (de)	2008-11-15	Phosphoindole als hiv-inhibitoren
WO2007022219A3 (en)	2007-05-03	Dental composition comprising enzyme
RU2005111873A (ru)	2006-10-27	Средство с антикоагулянтной, антитромбоцитарной, антитромботической фибриндеполимеризационной и фибринолитической активностями
DK1729732T3 (da)	2009-08-10	Anioniske hydrogelmatricer med pH-afhængig frigivelse som lægemiddelbærere
EP1809646A4 (en)	2009-05-06	GLYCIN RIBOSWITCHE, METHOD FOR THEIR USE AND COMPOSITIONS FOR USE WITH GLYCIN RIBOSWITCHES
IL187160A0 (en)	2008-02-09	Compositions and methods for treating hiv infection with cupredoxin and cytochrome c
WO2006014422A3 (en)	2009-04-09	Polynucleotide encoding a trim-cyp polypeptide, compositions thereof, and methods of using same
CU20070072A7 (es)	2009-09-08	Uso de [d-meala]3-[etval]4-ciclosporina para el tratamiento de infección por hepatitis c y composición farmacéutica que comprende la [d-meala]3-[etval]4-ciclosporina
FR2924338B1 (fr)	2010-09-03	Composition de coiffage comprenant au moins un copolymere (meth)acrylique et au moins un agent nacrant.
FR2894980B1 (fr)	2012-05-04	Compositions aqueuses epaissantes et limpides, leur utilisation dans des formulations aqueuses acides, formulations obtenues.
JPH10194986A5 (da)	2005-03-03
SV2007002216A (es)	2007-12-12	Nueva combinacion antiparasitaria de principios activos ref. bhc041312-sv
WO2007065032A3 (en)	2007-12-13	Compounds and methods for inhibiting viral entry
陈惠凤	2004	The Influence of Hemingway's Personal Experiences Over His Artistic Features and Central Figures